scholarly journals Long-term Outcomes of Childhood Onset Nephrotic Syndrome

2016 ◽  
Vol 4 ◽  
Author(s):  
Rebecca Hjorten ◽  
Zohra Anwar ◽  
Kimberly Jean Reidy
2016 ◽  
Vol 29 (1) ◽  
pp. 22-26
Author(s):  
Taichi Hara ◽  
Shuichiro Fujinaga ◽  
Akihumi Yamada ◽  
Yasuko Urusihara ◽  
Yoshiyuki Ootomo ◽  
...  

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Jeong-Seon Lee ◽  
Joong-Gon Kim ◽  
Soyoung Lee

AbstractChildhood-onset polyarteritis nodosa (PAN) is a rare and systemic necrotising vasculitis in children affecting small- to medium-sized arteries. To date, there have been only a few reports because of its rarity. Thus, we aimed to investigate the clinical manifestations, laboratory findings, treatment, and long-term outcomes in patients with childhood-onset PAN and to evaluate the usefulness of the paediatric vasculitis activity score (PVAS). We retrospectively analysed the data of nine patients with childhood-onset PAN from March 2003 to February 2020. The median ages at symptom onset, diagnosis, and follow-up duration were 7.6 (3–17.5), 7.7 (3.5–17.6), and 7.0 (1.6–16.3) years, respectively. All patients had constitutional symptoms and skin manifestations, while five exhibited Raynaud’s phenomenon. Organ involvement was observed in one patient. The median PVAS at diagnosis was 7 (range: 2–32). Prednisolone was initially used for induction in all patients, and other drugs were added in cases refractory to prednisolone. All patients survived, but three patients with high PVAS at diagnosis experienced irreversible sequelae, including intracranial haemorrhage and digital amputation. In conclusion, early diagnosis and treatment may minimise sequelae in patients with childhood-onset PAN. This study suggests that high PVAS score at diagnosis may be associated with poor prognosis.


BMJ Open ◽  
2020 ◽  
Vol 10 (9) ◽  
pp. e037306
Author(s):  
Julien Hogan ◽  
Aubriana Perez ◽  
Anne-Laure Sellier-Leclerc ◽  
Isabelle Vrillon ◽  
Francoise Broux ◽  
...  

IntroductionGuidelines for the treatment of steroid-dependent nephrotic syndrome (SDNS) and frequently relapsing nephrotic syndrome (FRNS) are lacking. Given the substantial impact of SDNS/FRNS on quality of life, strategies aiming to provide long-term remission while minimising treatment side effects are needed. Several studies confirm that rituximab is effective in preventing early relapses in SDNS/FRNS; however, the long-term relapse rate remains high (~70% at 2 years). This trial will assess the association of intravenous immunoglobulins (IVIgs) to rituximab in patients with SDNS/FRNS and inform clinicians on whether IVIg’s immunomodulatory properties can alter the course of the disease and reduce the use of immunosuppressive drugs and their side effects.Methods and analysisWe conduct an open-label multicentre, randomised, parallel group in a 1:1 ratio, controlled, superiority trial to assess the safety and efficacy of a single infusion of rituximab followed by IVIg compared with rituximab alone in childhood-onset FRNS/SDNS. The primary outcome is the occurrence of first relapse within 24 months. Patients are allocated to receive either rituximab alone (375 mg/m²) or rituximab followed by IVIg, which includes an initial Ig dose of 2 g/kg, followed by 1.5 g/kg injections once a month for the following 5 months (maximum dose: 100 g).Ethics and disseminationThe study has been approved by the ethics committee (Comité de Protection des Personnes) of Ouest I and authorised by the French drug regulatory agency (Agence Nationale de Sécurité du Médicament et des Produits de Santé). Results of the primary study and the secondary aims will be disseminated through peer-reviewed publications.Trial registration numberNCT03560011.


2018 ◽  
Vol 34 (2) ◽  
pp. 353-357 ◽  
Author(s):  
Shuichiro Fujinaga ◽  
Tomohiko Nishino ◽  
Chisato Umeda ◽  
Yuji Tomii ◽  
Yoshitaka Watanabe ◽  
...  

2014 ◽  
Vol 81 (03) ◽  
pp. 166-173 ◽  
Author(s):  
Piotr Skrzypczyk ◽  
MaÅ‚gorzata PaÅ„czyk- Tomaszewska ◽  
Maria Roszkowska-Blaim ◽  
Zofia Wawer ◽  
Beata BieniaÅ› ◽  
...  

2020 ◽  
Vol 5 (4) ◽  
pp. 426-434 ◽  
Author(s):  
Simon A. Carter ◽  
Shilan Mistry ◽  
Jessica Fitzpatrick ◽  
Tonny Banh ◽  
Diane Hebert ◽  
...  

2014 ◽  
Vol 29 (11) ◽  
pp. 2084-2091 ◽  
Author(s):  
Joëlle Guitard ◽  
Anne-Laure Hebral ◽  
Fadi Fakhouri ◽  
Dominique Joly ◽  
Eric Daugas ◽  
...  

2021 ◽  
Vol 12 ◽  
Author(s):  
Zheng Liangrong ◽  
Zhang Guican ◽  
Zhu Qi ◽  
Yang Weirui ◽  
Zhang Yaqi ◽  
...  

Objectives: The long-term outcome of childhood-onset schizophrenia (COS) and its influencing factors remain unclear. The current study aimed to assess the long-term outcomes of COS and identify possible outcome predictors.Methods: We retrospectively investigated 276 patients with COS. Diagnosis made according to the ICD-10 criteria for schizophrenia, and the age of the first onset was ≤ 14 years. Follow-up was completed for 170 patients, with a median follow-up period of 5.6 years. Outcome variables included occupational/education status and readmission. Spearman correlation was performed to assess the relationship between predictors and outcome variables. Binary logistic regression was conducted to detect possible predictor variables for outcome variables.Results: At the end of the follow-up, 89 patients (52.3%) were at school, 70 patients (41.2%) were employed, and only 11 patients (6.5%) were dropped out of school or unemployed. The duration to the first admission and depressive symptoms were identified as predictors of occupational/educational status. The length of follow-up and obsessive-compulsive symptoms (OCS) were distinguished as predictors of readmission. Duration to the first admission and length of follow-up were risk factors, and depressive symptoms and OCS were protective factors for the outcomes of COS.Conclusion: We found a favorable long-term outcome on occupational/education status in COS, and depressive symptoms and OCS may be associated with more positive long-term outcomes in COS. Our findings suggest that COS patients may benefit from early intervention and require appropriate treatment.


Sign in / Sign up

Export Citation Format

Share Document